These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 28511565)
1. The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Cerovska E; Elsnerova K; Vaclavikova R; Soucek P Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):741-753. PubMed ID: 28511565 [TBL] [Abstract][Full Text] [Related]
3. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Lukanović D; Herzog M; Kobal B; Černe K Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116 [TBL] [Abstract][Full Text] [Related]
4. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Alharbi M; Zuñiga F; Elfeky O; Guanzon D; Lai A; Rice GE; Perrin L; Hooper J; Salomon C Endocr Relat Cancer; 2018 Dec; 25(12):R663-R685. PubMed ID: 30400025 [TBL] [Abstract][Full Text] [Related]
5. The role of ABC transporters in ovarian cancer progression and chemoresistance. Ween MP; Armstrong MA; Oehler MK; Ricciardelli C Crit Rev Oncol Hematol; 2015 Nov; 96(2):220-56. PubMed ID: 26100653 [TBL] [Abstract][Full Text] [Related]
6. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946 [TBL] [Abstract][Full Text] [Related]
7. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Suh DH; Kim MK; No JH; Chung HH; Song YS Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839 [TBL] [Abstract][Full Text] [Related]
8. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861 [TBL] [Abstract][Full Text] [Related]
9. The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer. Qu J; Kamal MA; Yuan C Curr Pharm Des; 2019; 25(8):856-861. PubMed ID: 30947657 [TBL] [Abstract][Full Text] [Related]
10. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Kim A; Serada S; Enomoto T; Naka T Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185 [TBL] [Abstract][Full Text] [Related]
11. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer. Tang W; Ren A; Xiao H; Sun H; Li B Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706 [TBL] [Abstract][Full Text] [Related]
13. High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells. Volkmann J; Reuning U; Rudelius M; Häfner N; Schuster T; Becker V Ros A; Weimer J; Hilpert F; Kiechle M; Dürst M; Arnold N; Schmalfeldt B; Meindl A; Ramser J Int J Cancer; 2013 Jun; 132(12):2820-32. PubMed ID: 23225306 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. Kang KW; Lee MJ; Song JA; Jeong JY; Kim YK; Lee C; Kim TH; Kwak KB; Kim OJ; An HJ Oncol Rep; 2014 Jul; 32(1):189-98. PubMed ID: 24858567 [TBL] [Abstract][Full Text] [Related]
15. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338 [TBL] [Abstract][Full Text] [Related]
16. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408 [TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in ovarian cancer biology and therapy resistance. van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225 [TBL] [Abstract][Full Text] [Related]
18. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025 [TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Guestini F; McNamara KM; Ishida T; Sasano H Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563 [TBL] [Abstract][Full Text] [Related]
20. New players in ovarian cancer. Bovicelli A; D'Andrilli G; Giordano A J Cell Physiol; 2011 Oct; 226(10):2500-4. PubMed ID: 21302305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]